Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

NICE rejects Takeda cancer drug over price concerns

July 12, 2010
Sales and Marketing Cancer, Mepact, NICE, Takeda, bone cancer

UK cost-effectiveness watchdog NICE has rejected Takeda’s orphan bone cancer drug Mepact due to concerns over price. In its draft …

News

Digital Pharma: NICE launches mobile evidence service

July 9, 2010
Medical Communications Digital Pharma blog, NHS Evidence, NICE, evidence-based medicine

NICE has launched a mobile version of its online clinical evidence portal NHS Evidence. The beta version of the service …

News

NICE poised to reject Novartis’ Afinitor

July 8, 2010
Sales and Marketing Afinitor, NICE, Novartis

Novartis’ kidney cancer drug Afinitor does not offer enough benefit to patients to justify its cost, according to draft guidance …

News
Herceptin packs

NICE set to block Herceptin for gastric cancer

July 6, 2010
Sales and Marketing Herceptin, NICE, Roche, gastric cancer

NICE’s preliminary draft guidance has not approved Roche’s Herceptin for gastric cancer as it failed to show how far the …

News

NICE thumbs up for Roche arthritis drug

July 2, 2010
Sales and Marketing NICE, RoActemra, Roche

NICE has given preliminary approval to Roche’s RoActemra as an additional option for the treatment of moderate to severe rheumatoid …

News
Glivec pack

Higher dose of Glivec not cost effective, says NICE

June 29, 2010
Sales and Marketing Glivec, NICE, gastric cancer

 

News

NICE re-thinks arthritis guidance

June 25, 2010
Sales and Marketing Enbrel, Humira, MabThera, NICE, Orencia, Remicade, TNF, rheumatoid arthritis

NICE has approved five rheumatoid arthritis treatments in certain circumstances after treatment with a tumour necrosis factor inhibitor has failed. …

News

NICE rejects Glivec as adjuvant therapy

June 24, 2010
Sales and Marketing Glivec, NICE, Novartis

NICE has rejected the use of Novartis’ Glivec as an adjuvant treatment for people who have had a gastrointestinal stromal …

News
Ecteinascidia turbinata

NICE rejects Yondelis in ovarian cancer

June 21, 2010
Sales and Marketing NICE, PharmaMar, Yondelis, ovarian cancer

New cancer treatment Yondelis has been rejected by NICE in a preliminary ruling on its use in relapsed ovarian cancer. …

News

Prolia gets early thumbs up from NICE

June 18, 2010
Sales and Marketing Amgen, NICE, Prolia

Amgen’s new treatment to prevent bone fractures caused by osteoporosis has been given preliminary approval from the UK’s cost effectiveness …

News
Tarceva

NICE rejects Tarceva maintenance treatment

June 17, 2010
Sales and Marketing NICE, NSCLC, Roche, Tarceva, lung cancer

Roche’s Tarceva should not be used in lung cancer patients who have already been treated and whose disease remains stable, …

News
Victoza pack

Victoza wins partial NICE recommendation

June 15, 2010
Sales and Marketing NICE, Victoza, diabetes

Novo Nordisk has been given a limited approval for its new type II diabetes treatment in draft guidance issued by …

News

NICE rejects GSK’s Revolade

June 10, 2010
Sales and Marketing ITP, NICE, Revolade

NICE has rejected GlaxoSmithKline’s Revolade saying in draft guidance that the blood disorder drug’s benefits were unclear. The watchdog assessed …

News
TyverbWeb

NICE says no to GSK breast cancer drug

June 10, 2010
Sales and Marketing NICE, Tyverb

NICE has issued final draft guidance restricting use of GlaxoSmithKline’s breast cancer drug Tyverb to clinical trials, citing high cost …

News

NICE rejects Xolair for children

June 3, 2010
Sales and Marketing NICE, Xolair, asthma

The drug was first approved in Europe in November 2005 for patients aged 12 or older, and gained NICE approval …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026